Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in Adults with Hematologic Malignancies: A Phase III, Randomized Clinical Trial

por Oostvogels, Lidia
Publicado 2017

Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults Previously Vaccinated with a Live-Attenuated Herpes Zoster Vaccine: A Phase III, Group-Matc...

por Grupping, Katrijn, Campora, Laura, Douha, Martine, Heineman, Thomas C, Klein, Nicola P, Lal, Himal, Peterson, James, Oostvogels, Lidia
Publicado 2017

Assessment of the potential public health impact of Herpes Zoster vaccination in Germany

por Curran, Desmond, Van Oorschot, Desirée, Varghese, Lijoy, Oostvogels, Lidia, Mrkvan, Tomas, Colindres, Romulo, von Krempelhuber, Alfred, Anastassopoulou, Anastassia
Publicado 2017

Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine

por Grupping, Katrijn, Campora, Laura, Douha, Martine, Heineman, Thomas C, Klein, Nicola P, Lal, Himal, Peterson, James, Vastiau, Ilse, Oostvogels, Lidia
Publicado 2017

Selection of an adjuvant for seasonal influenza vaccine in elderly people: modelling immunogenicity from a randomized trial

por Rümke, Hans C, Richardus, Jan Hendrik, Rombo, Lars, Pauksens, Karlis, Plaßmann, Georg, Durand, Christelle, Devaster, Jeanne-Marie, Dewé, Walthère, Oostvogels, Lidia
Publicado 2013

A Third Dose of the COVID-19 Vaccine, CVnCoV, Increased the Neutralizing Activity against the SARS-CoV-2 Wild-Type and Delta Variant

por Wolz, Olaf-Oliver, Kays, Sarah-Katharina, Junker, Helga, Koch, Sven D., Mann, Philipp, Quintini, Gianluca, von Eisenhart-Rothe, Philipp, Oostvogels, Lidia
Publicado 2022

Persistence of Immune Response to an Adjuvanted Varicella‐Zoster Virus Subunit Candidate Vaccine for up to Year 9 in Older Adults

por Pauksens, Karlis, Volpe, Stephanie, Schwarz, Tino F, Smetana, Jan, Toursarkissian, Nicole, Rombo, Lars, Ravault, Stéphanie, David, Marie-Pierre, Bastidas, Adriana, Oostvogels, Lidia
Publicado 2017

2778. Impact of Reactogenicity on Quality of Life and Physical Functioning in Adults ≥50 Years Receiving Both Doses of the Adjuvanted Recombinant Zoster Vaccine

por Schmader, Kenneth E, Levin, Myron J, Chen, Michael, Matthews, Sean, Riley, Megan, Woo, Wayne, Hervé, Caroline, Grupping, Katrijn, Schuind, Anne, Oostvogels, Lidia, Curran, Desmond
Publicado 2019

Evaluation of two frailty indices, with practical application in a vaccine clinical trial

por Curran, Desmond, Andrew, Melissa K., Levin, Myron J., Turriani, Elisa, Matthews, Sean, Fogarty, Charles, Klein, Nicola P., Grupping, Katrijn, Oostvogels, Lidia, Schmader, Kenneth E.
Publicado 2019

1956. Persistence of Immune Response and Safety of an Adjuvanted Recombinant Zoster Vaccine in Older Adults Previously Vaccinated with a Live-Attenuated Herpes Zoster Vaccine: End-...

por Mrkvan, Tomas, Campora, Laura, Catteau, Grégory, Douha, Martine, Grupping, Katrijn, Herve, Caroline, Kalema, George, Heineman, Thomas, Klein, Nicola P, Lal, Himal, Oostvogels, Lidia, Schuind, Anne
Publicado 2018

2780. Reactogenicity Profile of Adjuvanted Recombinant Zoster Vaccine after Dose 2 According to the Intensity of the Same Event Experienced after Dose 1

por Colindres, Romulo, Wascotte, Valentine, Brecx, Alain, Clarke, Christopher, Hervé, Caroline, Hyung Kim, Joon, Levin, Myron J, Oostvogels, Lidia, Zahaf, Toufik, Schuind, Anne, Cunningham, Anthony L
Publicado 2019

Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials

por Colindres, Romulo, Wascotte, Valentine, Brecx, Alain, Clarke, Christopher, Hervé, Caroline, Kim, Joon Hyung, Levin, Myron J., Oostvogels, Lidia, Zahaf, Toufik, Schuind, Anne, Cunningham, Anthony L.
Publicado 2020

2905. Long-term Immunological Persistence of the Adjuvanted Recombinant Zoster Vaccine: Clinical Data and Mathematical Modeling

por Bastidas, Adriana, Catteau, Grégory, Volpe, Stéphanie, Mrkvan, Tomas, Enemuo, Adaora, Smetana, Jan, Schwarz, Tino, Rombo, Lars, Pauksens, Karlis, Berengier, Estelle, Hervé, Caroline, Oostvogels, Lidia, Schuind, Anne
Publicado 2019

Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial

por Aldrich, Cassandra, Leroux–Roels, Isabel, Huang, Katell Bidet, Bica, Mihai Alexandru, Loeliger, Edde, Schoenborn-Kellenberger, Oliver, Walz, Lisa, Leroux-Roels, Geert, von Sonnenburg, Frank, Oostvogels, Lidia
Publicado 2021

Impact of Reactogenicity After Two Doses of Recombinant Zoster Vaccine Upon Physical Functioning and Quality of Life: An Open Phase III Trial in Older Adults

por Schmader, Kenneth E, Levin, Myron J, Chen, Michael, Matthews, Sean, Riley, Megan E, Woo, Wayne, Hervé, Caroline, Grupping, Katrijn, Schuind, Anne E, Oostvogels, Lidia, Curran, Desmond
Publicado 2020

Superior antigen-specific CD4(+)T-cell response with AS03-adjuvantation of a trivalent influenza vaccine in a randomised trial of adults aged 65 and older

por Couch, Robert B, Bayas, José M, Caso, Covadonga, Mbawuike, Innocent Nnadi, López, Concepción Núñez, Claeys, Carine, El Idrissi, Mohamed, Hervé, Caroline, Laupèze, Béatrice, Oostvogels, Lidia, Moris, Philippe
Publicado 2014

5. How Does Frailty Impact the Efficacy, Reactogenicity, Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine? A Secondary Analysis of the ZOE-50 and ZOE-70 Studi...

por Andrew, Melissa K, Kim, Joon Hyung, Matthews, Sean, Dessart, Christophe, levin, myron J, Oostvogels, Lidia, Riley, Megan, Schmader, Kenneth E, McNeil, Shelly, Schuind, Anne, Curran, Desmond
Publicado 2020

2779. Efficacy of the Adjuvanted Recombinant Zoster Vaccine According to Sex, Geographic Region, and Geographic Ancestry/Ethnicity: A Post-hoc Analysis

por Willer, David O, Wascotte, Valentine, Kim, Joon Hyung, Zahaf, Toufik, Talarico, Carla, Gorfinkel, Iris, Gervais, Pierre, Pharm, Pharm, L, Cunningham, Anthony L, Oostvogels, Lidia, Colindres, Romulo, Schuind, Anne
Publicado 2019

Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine Coadministered With Seasonal Influenza Vaccine in Adults Aged 50 Years or Older

por Schwarz, Tino F, Aggarwal, Naresh, Moeckesch, Beate, Schenkenberger, Isabelle, Claeys, Carine, Douha, Martine, Godeaux, Olivier, Grupping, Katrijn, Heineman, Thomas C, Fauqued, Marta Lopez, Oostvogels, Lidia, Van den Steen, Peter, Lal, Himal
Publicado 2017

Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults

por Schwarz, Tino F., Volpe, Stephanie, Catteau, Gregory, Chlibek, Roman, David, Marie Pierre, Richardus, Jan Hendrik, Lal, Himal, Oostvogels, Lidia, Pauksens, Karlis, Ravault, Stephanie, Rombo, Lars, Sonder, Gerard, Smetana, Jan, Heineman, Thomas, Bastidas, Adriana
Publicado 2018